OCGN Stock Summary and Trading Ideas (Ocugen | NASDAQ:OCGN)

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Ocugen trades on the NASDAQ stock market under the symbol OCGN.

As of November 8, 2024, OCGN stock price declined to $0.99 with 7,891,950 million shares trading.

OCGN has a beta of 1.90, meaning it tends to be more sensitive to market movements. OCGN has a correlation of 0.05 to the broad based SPY ETF.

OCGN has a market cap of $283.82 million. This is considered a Small Cap stock.

In the last 3 years, OCGN traded as high as $10.40 and as low as $.35.

The top ETF exchange traded funds that OCGN belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.

OCGN has outperformed the market in the last year with a price return of +159.8% while the SPY ETF gained +38.5%. However, in the short term, OCGN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -16.4% vs +15.7% return in SPY. But in the last 2 weeks, OCGN shares have fared better than the market returning +10.4% compared to SPY +3.3%.

OCGN support price is $1.03 and resistance is $1.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCGN shares will trade within this expected range on the day.